United in the search for better treatments
The Critical Path for Parkinson's meeting brought together pharmaceutical companies, universities, charities and regulatory bodies to address barriers to new treatments.
New Sheffield based Virtual Biotech programme aims to save brain cells
We’re investing £100,000 to improve compounds that have the potential to boost the function of brain cell batteries and slow the progression of Parkinson’s.
£1.5 million investment in Parkinson’s UK Brain Bank
We're investing £1.5 million over 5 years in our Brain Bank, powering new research to understand more about Parkinson's.
New device improves Parkinson’s symptoms
Researchers have shown that an ‘easy to use’ portable stimulation headset may be able to reduce both motor and non-motor symptoms of Parkinson’s.
Could a gut infection trigger Parkinson's?
A new study published in Nature has shown that a gut infection can lead to symptoms resembling Parkinson's in mice, suggesting that the immune system may play a more central role in the condition than previously thought.
Targeting nerve cell batteries to slow Parkinson’s progression
We’re investing nearly £1 million to find a new treatment that targets energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
New research puts serotonin at the heart of Parkinson’s
In a seminal research paper, published in Lancet Neurology, researchers from King’s College London have used brain scans to uncover early changes in the brain that may happen years before the symptoms of Parkinson's appear.
HYPE protein found to target alpha-synuclein
Researchers in the US have identified a protein in the brain that may reduce the spread of the toxic alpha-synuclein protein in Parkinson's.
Targeting bacteria in the gut could increase effectiveness of levodopa
New research from Harvard University suggests changes to the gut could improve how a common Parkinson’s medication works.
New molecules targeting alpha-synuclein have potential for slowing Parkinson’s
Researchers in Japan have developed molecules that could be key to slowing the progression of Parkinson’s.